within Pharmacolibrary.Drugs.ATC.N;

model N06AX28
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.92,
    Cl             = 0.000365,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.387,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01933333333333333,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX28</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder (MDD) in adults. It is the more active enantiomer of milnacipran and is approved for use in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after administration of oral levomilnacipran extended release. Data are based on population PK analysis in both male and female adults.</p><h4>References</h4><ol><li><p>Shelton, RC (2019). Serotonin and Norepinephrine Reuptake Inhibitors. <i>Handbook of experimental pharmacology</i> 250 145–180. DOI:<a href=&quot;https://doi.org/10.1007/164_2018_164&quot;>10.1007/164_2018_164</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30838456/&quot;>https://pubmed.ncbi.nlm.nih.gov/30838456</a></p></li><li><p>Chen, L, et al., &amp; Ghahramani, P (2014). Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. <i>Clinical drug investigation</i> 34(5) 351–359. DOI:<a href=&quot;https://doi.org/10.1007/s40261-014-0182-5&quot;>10.1007/s40261-014-0182-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24677141/&quot;>https://pubmed.ncbi.nlm.nih.gov/24677141</a></p></li><li><p>Chen, L, et al., &amp; Ghahramani, P (2015). Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. <i>Drug design, development and therapy</i> 9 3293–3300. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S85418&quot;>10.2147/DDDT.S85418</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26150701/&quot;>https://pubmed.ncbi.nlm.nih.gov/26150701</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX28;
